ArticleScientific reports2022
Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- High SNHG expression may contribute to poor cervical cancer prognosis, based on systematic reviews and meta-analyses.BMC cancer · 2025Pooled it
- Survival status of women with cervical cancer in Sub-Saharan Africa: a systematic review and meta-analysis, 2024.Frontiers in oncology · 2024Pooled it
- Sociodemographic disparities and hospice referral practice patterns among patients with recurrent cervical cancer.Gynecologic oncology reports · 2026Article
- Nobiletin attenuates self-renewal in cervical cancer cells and spheres through miR-342-3p upregulation and FOXM1 downregulation.Molecular and cellular biochemistry · 2026Article
- Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer.Obstetrics & gynecology science · 2026Article
- Burden and predictors of cervical cancer mortality in Sub-Saharan Africa: a systematic review and meta-analysis.Infectious agents and cancer · 2026Review
- Article
- MUL1 suppresses cervical cancer progression by targeting FUNDC1 for ubiquitination and inhibiting DRP1-dependent mitophagy.Journal of molecular histology · 2026Article
- The correlation between the systemic immune-inflammation index and relapse and metastasis in cervical squamous cell carcinoma patients over 50 years and older.BMC immunology · 2026Article
- Comparison of efficacy and safety of definitive chemoradiotherapy for cervical cancer patients of different age groups using propensity score matching.Discover oncology · 2026Article
- Prognostic factors and outcomes of CT-guided Iodine-125 seed brachytherapy for retroperitoneal lymph node metastases from a previously irradiated field in cervical carcinoma: a multicenter retrospective study.Frontiers in oncology · 2026Article
- HPV Genotypes and Survival Outcomes in Invasive Cervical Cancer: A Retrospective Molecular Analysis of FFPE Clinical Samples in an Iranian Cohort.International journal of women's health · 2026Article
- Medicaid expansion and overall mortality among women with cervical cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Unraveling the mechanisms of LncRNAs in cervical cancer: a comprehensive review.Cell death discovery · 2025Review
- Integrative Long Non-Coding RNA Analysis and Recurrence Prediction in Cervical Cancer Using a Recurrent Neural Network.Diagnostics (Basel, Switzerland) · 2025Article
- Downregulation ofTranslational cancer research · 2025Article
- Sacral Neuromodulation for Post-Hysterectomy Hydroureteronephrosis in a Patient with Cervical Cancer: A Case Report.The American journal of case reports · 2025Article
- Comparative study of five-year cervical cancer cause-specific survival prediction models based on SEER data.Scientific reports · 2025Article
- Integrating Clinical and Transcriptomic Profiles Associated with Vitamin D to Enhance Disease-Free Survival in Cervical Cancer Recurrence Using the CatBoost Algorithm.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the recurrence rate and overall survival for patients with cervical cancer after the first treatment and the related risk factors. A retrospective cohort study was conducted on cervical cancer patients enrolled in a cancer specialist hospital in Hunan Province, China from January 1992 to December 2005 and followed up until December 2010. Kaplan-Meier survival analysis was used to estimate the cumulative recurrence rate, and Cox proportional hazards model was utilized to identify risk factors associated with prognosis. A total of 4358 patients were enrolled with a median follow-up of 7.4 years (range 5-19 years), and 372 (8.5%) patients had cancer recurrence. The cumulative recurrence rate showed a rapid increase from 3.8% in the first year after discharge to 8.0% in the fifth year, and the recurrence rate remained relatively stable afterward reaching 9.7% and 10.8% in the 10th and the 15th year, respectively. The median time to recurrence was 15.5 months with an IQR of 5.5-40.0 months. The Cox regression showed that miscarriage, clinical stage, and treatment received were significantly associated with cervical cancer recurrence after adjustment for confounders. Patients with recurrence showed a significantly higher risk for mortality than those without recurrence (HR 2.79, 95% CI 2.42-3.22). This study depicted the long-term recurrence rate and survival after recurrence for patients with cervical cancer after the first treatment, and reported time to recurrence and risk factors related to recurrence. These findings may provide important evidence for designing targeted interventions for the treatment of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.